MHRA-102482-PIP01-26

Key Facts

Active Substance
Active Substance:
  • Human rabies immune globulin
Invented Name
  • KAMRAB
  • KAMRAB
  • KAMRAB
  • PlasmaRAB
  • KAMRAB
  • KAMRAB
  • REBINOLIN
  • KAMRAB
  • REBINOLIN
  • KEDRAB
PIP Number MHRA-102482-PIP01-26
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Solution for injection
Therapeutic area
Therapeutic area:
  • Infectious diseases
Conditions / Indications
Conditions / Indications:
  • Prevention of rabies infection
Route(s) of administration
Route(s) of administration:
  • Intramuscular use
PIP applicant
  • Kamada Ireland Limited
  • Country Ireland
  • Tel +972522660030
  • Email oritp@kamada.com
Decision Type
Decision Type
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Human rabies immune globulin.pdf
Published Date 14/10/2026